CA3005103A1 - Process for making benzoxazepin compounds - Google Patents

Process for making benzoxazepin compounds

Info

Publication number
CA3005103A1
CA3005103A1 CA3005103A CA3005103A CA3005103A1 CA 3005103 A1 CA3005103 A1 CA 3005103A1 CA 3005103 A CA3005103 A CA 3005103A CA 3005103 A CA3005103 A CA 3005103A CA 3005103 A1 CA3005103 A1 CA 3005103A1
Authority
CA
Canada
Prior art keywords
bromo
acid
ethyl
solution
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3005103A
Other languages
English (en)
French (fr)
Inventor
Remy Angelaud
Danial BEAUDRY
Diane CARRERA
Sushant Malhotra
Travis Remarchuk
Fredric ST-JEAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA3005103A1 publication Critical patent/CA3005103A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3005103A 2013-03-13 2014-03-12 Process for making benzoxazepin compounds Abandoned CA3005103A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779619P 2013-03-13 2013-03-13
US61/779,619 2013-03-13
CA2948765A CA2948765A1 (en) 2013-03-13 2014-03-12 Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2948765A Division CA2948765A1 (en) 2013-03-13 2014-03-12 Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds

Publications (1)

Publication Number Publication Date
CA3005103A1 true CA3005103A1 (en) 2014-09-18

Family

ID=50241450

Family Applications (6)

Application Number Title Priority Date Filing Date
CA2897618A Abandoned CA2897618A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA2948763A Expired - Fee Related CA2948763C (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA2948765A Abandoned CA2948765A1 (en) 2013-03-13 2014-03-12 Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds
CA3005118A Abandoned CA3005118A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA3005112A Abandoned CA3005112A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA3005103A Abandoned CA3005103A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CA2897618A Abandoned CA2897618A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA2948763A Expired - Fee Related CA2948763C (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA2948765A Abandoned CA2948765A1 (en) 2013-03-13 2014-03-12 Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds
CA3005118A Abandoned CA3005118A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA3005112A Abandoned CA3005112A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds

Country Status (15)

Country Link
US (1) US9303043B2 (OSRAM)
EP (3) EP3845540A1 (OSRAM)
JP (6) JP6363120B2 (OSRAM)
KR (3) KR20180070715A (OSRAM)
CN (2) CN108929333A (OSRAM)
AR (1) AR095365A1 (OSRAM)
AU (3) AU2014230812B2 (OSRAM)
BR (1) BR112015020716A2 (OSRAM)
CA (6) CA2897618A1 (OSRAM)
IL (1) IL240793A0 (OSRAM)
MX (1) MX2015011438A (OSRAM)
NZ (1) NZ711192A (OSRAM)
RU (2) RU2649976C2 (OSRAM)
SG (2) SG10201706760YA (OSRAM)
WO (1) WO2014140073A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180093138A (ko) 2013-12-16 2018-08-20 에프. 호프만-라 로슈 아게 2-(4-(2-(1-이소프로필-3-메틸-1H-1,2,4-트라이아졸-5-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)-1H-피라졸-1-일)-2-메틸프로판아미드의 다형체, 이의 제조 방법 및 이의 약학적 용도
JP6522807B2 (ja) 2015-07-02 2019-05-29 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
CN112047960B (zh) * 2015-07-02 2024-08-02 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
CN105906635A (zh) * 2016-06-08 2016-08-31 上海大学 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
KR20190036549A (ko) 2016-07-29 2019-04-04 니뽄 다바코 산교 가부시키가이샤 피라졸-아미드 화합물의 제조 방법
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
KR102537048B1 (ko) 2016-12-15 2023-05-26 에프. 호프만-라 로슈 아게 (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노) 프로판아미드의 제조 방법
CN108752237A (zh) * 2018-07-05 2018-11-06 四川青木制药有限公司 一种对氨基苯甲脒盐酸盐的新制备方法
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
EP1123281B1 (en) * 1998-10-23 2003-10-22 Dow AgroSciences LLC 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds
JP4463548B2 (ja) 2001-07-12 2010-05-19 リアクサ・リミテッド マイクロカプセル化触媒、及びその製造法と使用法
EP1435951B1 (en) * 2001-10-12 2006-01-18 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the tretment of obesity
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
DK2081937T3 (da) 2006-10-23 2012-10-01 Sgx Pharmaceuticals Inc Triazolopyridazin-proteinkinasemodulatorer
DK2084162T3 (da) * 2006-10-23 2012-10-01 Sgx Pharmaceuticals Inc Bicykliske triazoler som proteinkinasemodulatorer
CA2675755C (en) * 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
WO2009105500A1 (en) * 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
WO2009123971A1 (en) 2008-03-31 2009-10-08 Genentech, Inc. Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
RU2600927C2 (ru) * 2009-09-28 2016-10-27 Ф.Хоффманн-Ля Рош Аг Бензоксазепиновые ингибиторы pi3k и способы применения
PE20140918A1 (es) 2009-09-28 2014-08-06 Hoffmann La Roche Compuestos de benzoxepina inhibidores de la pi3k
CA2778684A1 (en) * 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
CN102558167A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 Gk和ppar双重激动活性的噻唑烷二酮衍生物
RU2013143747A (ru) * 2011-03-21 2015-04-27 Ф. Хоффманн-Ля Рош Аг Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения
NO3175985T3 (OSRAM) * 2011-07-01 2018-04-28
EP2858666B1 (en) * 2012-06-08 2019-09-04 F.Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

Also Published As

Publication number Publication date
AU2018201393A1 (en) 2018-03-15
CA2897618A1 (en) 2014-09-18
SG10201706760YA (en) 2017-10-30
AU2014230812A8 (en) 2015-09-10
EP3404032B1 (en) 2025-07-02
AR095365A1 (es) 2015-10-14
JP6663459B2 (ja) 2020-03-11
AU2014230812A1 (en) 2015-09-03
WO2014140073A1 (en) 2014-09-18
SG11201507394RA (en) 2015-10-29
KR101821468B1 (ko) 2018-01-23
US9303043B2 (en) 2016-04-05
KR101871133B1 (ko) 2018-06-25
CA2948765A1 (en) 2014-09-18
EP2970329A1 (en) 2016-01-20
JP2020114814A (ja) 2020-07-30
CN108929333A (zh) 2018-12-04
CA2948763C (en) 2018-04-24
IL240793A0 (en) 2015-10-29
KR20170070270A (ko) 2017-06-21
AU2014230812B2 (en) 2016-04-07
JP2018150298A (ja) 2018-09-27
HK1215433A1 (zh) 2016-08-26
EP3404032A2 (en) 2018-11-21
AU2016204432A1 (en) 2016-07-21
JP2018008959A (ja) 2018-01-18
KR20150119033A (ko) 2015-10-23
RU2015138488A (ru) 2017-04-20
CN105377856A (zh) 2016-03-02
KR20180070715A (ko) 2018-06-26
JP6442005B2 (ja) 2018-12-19
AU2016204432B2 (en) 2017-12-07
EP3404032A3 (en) 2019-03-13
BR112015020716A2 (pt) 2017-07-18
RU2018109979A (ru) 2019-02-28
CA3005118A1 (en) 2014-09-18
US20140275523A1 (en) 2014-09-18
JP2019089762A (ja) 2019-06-13
JP2016512209A (ja) 2016-04-25
CA3005112A1 (en) 2014-09-18
MX2015011438A (es) 2016-02-03
EP3845540A1 (en) 2021-07-07
JP6363120B2 (ja) 2018-07-25
JP2019031493A (ja) 2019-02-28
CN105377856B (zh) 2018-05-22
CA2948763A1 (en) 2014-09-18
RU2649976C2 (ru) 2018-04-06
NZ711192A (en) 2019-04-26
EP3404032C0 (en) 2025-07-02

Similar Documents

Publication Publication Date Title
EP3404032B1 (en) Process for making benzoxazepin compounds
KR20220042204A (ko) Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
KR101698283B1 (ko) 티에노피리미딘 화합물의 제조 방법
WO2021092336A1 (en) Heterocyclic rip1 inhibitory compounds
WO2020079652A1 (en) Kinase inhibitors
CA2977752A1 (en) Benzimidazole compound for preventing or treating a disease caused by abnormal prs activity, method for preparing the same and pharmaceutical composition comprising the same
HK1215433B (zh) 制备苯并氧氮杂䓬化合物的方法
KR20190022416A (ko) 신규한 트립토판 수산화효소 저해제 및 이를 포함하는 약학적 조성물
EA021781B1 (ru) 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения
WO2025256640A1 (zh) 大环化合物及其药物组合物和应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180516

FZDE Discontinued

Effective date: 20200312